Intravenous delivery of an endostatin gene complexed in cationic lipid inhibits systemic angiogenesis and tumor growth in murine models.
作者： Paul Blezinger , Guoyong Yin , Liang Xie , Jijun Wang , Majed Matar
关键词:
摘要: Inhibition of the neovascularization tumors has proven efficacious in reducing tumor growth and metastases. Attaining antiangiogenesis through cationic lipid-based systemic gene therapy presents an attractive approach to treatment disseminated primary cancers. Intravenous administration endostatin plasmid, complexed with a lipid system, produced significant levels lung circulation. The expressed blocked angiogenesis inhibited murine models. Cytokine induction by lipid/DNA complex increased anti-tumor activities endostatin. These results demonstrate possibility using delivery antiangiogenic for cancer treatment.
springer.com
sci-hub.se 参考文章(22)
Lynn Hlatky, Melvin E. Clouse, Ernest F. Terwilliger, Ping Wu, Josephine T. Nguyen, Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Research. ,vol. 58, pp. 5673- 5677 ,(1998)
Thomas Boehm, Judah Folkman, Timothy Browder, Michael S. O'Reilly, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature. ,vol. 390, pp. 404- 407 ,(1997) , 10.1038/37126
Petrak Kl, Deshpande Ds, Freimark Bd, Long Sd, Blezinger Hp, Nochumson S, Florack Vj, Nordstrom Jl, Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. Journal of Immunology. ,vol. 160, pp. 4580- 4586 ,(1998)
A. James Mixson, Dhruv Kumar, Sanford A. Stass, Qing-Rong Chen, Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Research. ,vol. 59, pp. 3308- 3312 ,(1999)
H Li, H Lu, F Griscelli, P Opolon, L-Q Sun, T Ragot, Y Legrand, D Belin, J Soria, C Soria, M Perricaudet, P Yeh, Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Therapy. ,vol. 5, pp. 1105- 1113 ,(1998) , 10.1038/SJ.GT.3300742
Judah Folkman, Antiangiogenic gene therapy Proceedings of the National Academy of Sciences of the United States of America. ,vol. 95, pp. 9064- 9066 ,(1998) , 10.1073/PNAS.95.16.9064
Neil R. Hackett, Avner Yayon, Ronald G. Crystal, Hwai-Loong Kong, Dalit Hecht, Wenru Song, Imre Kovesdi, Regional Suppression of Tumor Growth by In Vivo Transfer of a cDNA Encoding a Secreted Form of the Extracellular Domain of the flt-1 Vascular Endothelial Growth Factor Receptor Human Gene Therapy. ,vol. 9, pp. 823- 833 ,(1998) , 10.1089/HUM.1998.9.6-823
P. Lin, J. A. Buxton, A. Acheson, C. Radziejewski, P. C. Maisonpierre, G. D. Yancopoulos, K. M. Channon, L. P. Hale, M. W. Dewhirst, S. E. George, K. G. Peters, Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2 Proceedings of the National Academy of Sciences of the United States of America. ,vol. 95, pp. 8829- 8834 ,(1998) , 10.1073/PNAS.95.15.8829
Yong Liu, Leslie C. Mounkes, H. Denny Liggitt, Carolyn S. Brown, Igor Solodin, Timothy D. Heath, Robert J. Debs, Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nature Biotechnology. ,vol. 15, pp. 167- 173 ,(1997) , 10.1038/NBT0297-167
M. Xu, D. Kumar, S.A. Stass, A.J. Mixson, Gene Therapy with P53 and a Fragment of Thrombospondin I Inhibits Human Breast Cancerin Vivo Molecular Genetics and Metabolism. ,vol. 63, pp. 103- 109 ,(1998) , 10.1006/MGME.1997.2654